Tag: MONOGRAPH

  • SM-04554

    Small-molecule Wnt/beta-catenin signaling pathway activator for topical dermatological application

    A synthetic 1,4-diketone Wnt pathway activator developed by Samumed (Biosplice Therapeutics) as a topical treatment for androgenetic alopecia, distinguished by its mechanism of follicular Wnt/beta-catenin signaling restoration and hair follicle neogenesis capacity in preclinical models, advanced through Phase 3 clinical evaluation before discontinuation.

    Abstract

    SM-04554, also designated dalosirvat (International Nonproprietary Name), is a synthetic small-molecule activator of the canonical Wnt/beta-catenin signaling pathway developed by Samumed, LLC (subsequently renamed Biosplice Therapeutics, Inc.) as a topical treatment for androgenetic alopecia (AGA). The compound activates Wnt signaling with an EC50 of approximately 28 to 29 nanomolar in cell-based reporter assays, producing increases in total and nuclear beta-catenin, versican expression, and Ki-67 proliferation marker specifically in hair follicle compartments. The molecular formula is C18H16O4 with a molecular weight of 296.32 g/mol; the compound is a 1,4-diketone bearing a 2,3-dihydro-1,4-benzodioxin-6-yl moiety and a terminal phenyl group, conferring moderate lipophilicity (calculated XLogP 2.6) suitable for topical scalp formulation.

    The mechanistic rationale for SM-04554 in androgenetic alopecia rests on the observation that Wnt/beta-catenin signaling is essential for the initiation and maintenance of the anagen (growth) phase of the hair cycle and that progressive reduction of Wnt pathway activity in the dermal papilla and hair bulge stem cell niche is a molecular correlate of follicular miniaturization in AGA. SM-04554 activates the pathway downstream of ligand-receptor interaction, increasing nuclear translocation of beta-catenin and transcription of Wnt target genes including those regulating dermal progenitor cell differentiation toward the hair follicle lineage. In preclinical models, topical SM-04554 induced hair follicle neogenesis in CD1 and C57BL/6 mice (2-fold increase in total follicle count after 4 days of treatment) and in Hanford mini-pigs (significant increase in vellus follicle number sustained through 112 days of observation following a 42-day treatment course).

    Clinical development proceeded through Phase 1 (29 subjects, 14-day topical application at 0.05%, 0.15%, and 0.45% concentrations), Phase 2 (two studies: a 49-subject biopsy-endpoint trial and a 300-subject efficacy trial, both 90-day treatment), and Phase 3 (625-subject registration trial initiated November 2018 and completed January 2021). The Phase 1 trial demonstrated safety with only one drug-related adverse event (eye irritation at the 0.45% concentration). The Phase 2 program demonstrated statistically significant increases in non-vellus hair count and density at the 0.15% concentration relative to vehicle, with an inverted-U dose-response in which the 0.15% concentration outperformed the higher 0.25% concentration. Adverse events across the Phase 2 program were mild (scalp redness, burning, stinging) and comparable in frequency to vehicle. No serious adverse events were reported in any treated patient across the Phase 2 program. The Phase 3 trial results were not publicly disclosed; Biosplice Therapeutics removed SM-04554 from its development pipeline in 2021, and a 2023 literature review confirmed cancellation of development based on Phase 3 outcomes. The compound is not approved by any regulatory authority.

    SM-04554 is one component of a broader Wnt-modulating therapeutic platform developed by Samumed/Biosplice, which includes lorecivivint (SM-04690, a CLK2/DYRK1A kinase inhibitor for knee osteoarthritis) and SM-04755 (a Wnt pathway inhibitor for tendinopathy). The compound is available from multiple research chemical suppliers as a white powder at greater than 99% purity. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Aticaprant

    Selective kappa-opioid receptor (KOR) antagonist with short-acting, non-inactivating pharmacodynamic profile

    A potent, orally bioavailable aminobenzyloxyarylamide kappa-opioid receptor antagonist developed at Eli Lilly and advanced through Phase 3 clinical evaluation for adjunctive treatment of major depressive disorder with anhedonia, distinguished from earlier KOR antagonists by favorable drug-like properties, short-acting receptor blockade, and a well-characterized safety profile.

    Abstract

    Aticaprant (LY-2456302, CERC-501, JNJ-67953964) is a potent, selective, orally bioavailable antagonist of the kappa-opioid receptor (KOR) with a binding affinity (Ki) of 0.81 nM, approximately 30-fold selectivity over the mu-opioid receptor (Ki = 24.0 nM), and approximately 190-fold selectivity over the delta-opioid receptor (Ki = 155 nM). The compound belongs to the aminobenzyloxyarylamide chemical class and was designed at Eli Lilly Research Laboratories as a clinically viable therapeutic targeting the endogenous dynorphin/KOR neuromodulatory system, a pathway implicated in the pathophysiology of stress-induced anhedonia, dysphoria, and addictive behaviors. In contrast to earlier KOR antagonists such as JDTic and nor-binaltorphimine, which exhibit ultra-long-duration receptor inactivation persisting for weeks after a single dose, aticaprant produces short-acting, reversible KOR blockade with an elimination half-life of 30 to 40 hours, enabling conventional once-daily oral dosing and predictable pharmacokinetic management.

    In rodent behavioral models, aticaprant produced antidepressant-like effects in the mouse forced swim test, enhanced the efficacy of imipramine and citalopram, reduced ethanol self-administration in alcohol-preferring (P) rats, and reversed unpredictable chronic mild stress-induced anhedonia in C57BL/6J mice, as measured by sucrose preference, nest building, and forced swim endpoints.

    Clinical development of aticaprant has proceeded through multiple sponsors. Eli Lilly conducted the initial Phase 1 single- and multiple-ascending dose studies (Lowe et al. 2014), establishing safety, tolerability, and the absence of clinically significant interactions with ethanol. Cerecor Inc. acquired the compound in 2015 and initiated early clinical studies in mood and substance use disorders. Janssen Pharmaceuticals (Johnson and Johnson) acquired the compound in 2017 and advanced it through Phase 2 and Phase 3 programs for adjunctive treatment of major depressive disorder (MDD) in patients with inadequate response to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). The Phase 2 randomized, double-blind, placebo-controlled study (Jacobsen et al. 2024) in 181 participants with MDD and moderate-to-severe anhedonia demonstrated a statistically significant reduction of 2.1 points on the Montgomery-Asberg Depression Rating Scale (MADRS) for aticaprant 10 mg versus placebo (p = 0.04), with favorable tolerability and no new safety signals. However, the compound did not separate from placebo on secondary measures of anhedonia (Snaith-Hamilton Pleasure Scale), global illness severity (CGI-S), anxiety (HAM-A), or patient-reported depression outcomes.

    Janssen subsequently initiated the VENTURA Phase 3 program comprising five pivotal trials in MDD with anhedonia. On 6 March 2025, Johnson and Johnson announced discontinuation of the VENTURA program due to insufficient efficacy in the target population, while noting that the compound remained safe and well tolerated with no new safety signals detected. The most common treatment-emergent adverse events in clinical trials were headache (11.8% versus 7.1% placebo), diarrhea (8.2% versus 2.4%), nasopharyngitis (5.9% versus 2.4%), and pruritus (5.9% versus 0%). Johnson and Johnson has indicated that it will explore future development opportunities for aticaprant in other areas of high unmet need. The compound is not approved by any regulatory authority for any indication. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • ITPP

    Synthetic membrane-permeant allosteric effector of hemoglobin (inositol pyrophosphate class)

    A first-in-class inositol pyrophosphate designed to cross the erythrocyte membrane, reduce hemoglobin oxygen affinity via right-shift of the oxyhemoglobin dissociation curve, and enhance regulated oxygen delivery to hypoxic tissues, with preclinical and early clinical investigation across oncology, cardiovascular, and metabolic indications.

    Abstract

    Myo-inositol trispyrophosphate (ITPP) is a synthetic pyrophosphate derivative of phytic acid that functions as a membrane-permeant allosteric effector of hemoglobin, reducing the affinity of hemoglobin for oxygen and shifting the oxyhemoglobin dissociation curve to the right, thereby enhancing the release of molecular oxygen from erythrocytes into tissues under conditions of low partial pressure of oxygen. The compound was conceived in the laboratory of Jean-Marie Lehn (Nobel Laureate in Chemistry, 1987) and Claude Nicolau in the early 2000s as a rationally designed analog of the endogenous erythrocyte effector 2,3-diphosphoglycerate (2,3-DPG), engineered to bear three cyclic pyrophosphate rings on the myo-inositol scaffold that confer net negative charge sufficient to bind the positively charged central cavity of deoxyhemoglobin while maintaining membrane permeability across the erythrocyte plasma membrane via the band 3 anion transport complex. Unlike 2,3-DPG and the structurally related phytic acid (inositol hexakisphosphate), which cannot traverse the red blood cell membrane, ITPP enters the erythrocyte intact and engages the allosteric T-state binding site of hemoglobin in situ, producing a dose-dependent rightward shift of the P50 (the partial pressure of oxygen at which hemoglobin is 50 percent saturated) without altering cooperativity or total oxygen-carrying capacity.

    The preclinical pharmacology of ITPP spans three principal therapeutic domains. In oncology, ITPP-mediated tumor reoxygenation produces downregulation of hypoxia-inducible factor 1-alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), normalization of tumor vasculature through activation of the endothelial PTEN/AKT signaling axis, and potentiation of subsequent chemotherapy and radiation therapy in rodent models of pancreatic, hepatocellular, colorectal, melanoma, glioblastoma, and rhabdomyosarcoma tumors. In cardiovascular medicine, ITPP treatment in rodent models of myocardial infarction and monocrotaline-induced pulmonary hypertension has produced improved myocardial oxygenation, attenuation of adverse left and right ventricular remodeling, reduction of pulmonary hypertension-related mortality, and dose-dependent increases in maximal exercise capacity of up to 57 percent in normal mice and 63 percent in transgenic mice with severe heart failure. In metabolism, ITPP has demonstrated reduction of adipose tissue accumulation in high-fat-diet rodent models through reversal of adipose tissue hypoxia.

    The compound was well tolerated, with the principal treatment-related adverse event being asymptomatic hypercalcemia attributable to calcium chloride in the formulation rather than to the compound itself. Pharmacokinetic analysis demonstrated dose-proportional exposure with a terminal half-life of 1.3 to 3.3 hours, no systemic accumulation, and plasma clearance of 3.1 to 4.8 L/h. Morphological disease stabilization was observed in 52 percent of patients under ITPP monotherapy, and subsequent chemotherapy produced stable disease in 60 percent and partial response in 10 percent. Decreases in circulating angiogenic markers (VEGFA, angiopoietin-1, angiopoietin-2, EGF, PECAM1) were observed in a majority of patients and correlated with improved survival following chemotherapy. ITPP is prohibited in competitive sport by the World Anti-Doping Agency as a substance with potential to enhance oxygen transfer, and analytical methods for its detection in human urine and equine plasma have been developed for anti-doping enforcement.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tadalafil

    Selective phosphodiesterase type 5 (PDE5) inhibitor with secondary PDE11 activity

    A long-acting beta-carboline-derived cyclic GMP phosphodiesterase inhibitor developed by ICOS and Eli Lilly for erectile dysfunction, subsequently approved for benign prostatic hyperplasia and pulmonary arterial hypertension, distinguished from other PDE5 inhibitors by a 17.5-hour plasma half-life, food-independent absorption, and emerging preclinical interest in neuroprotection and cognitive enhancement.

    Abstract

    Tadalafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), approved by the United States Food and Drug Administration for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Structurally a beta-carboline (pyrazinopyridoindole) derivative bearing a methylenedioxyphenyl substituent, tadalafil is chemically and pharmacologically distinct from the pyrimidinone-based PDE5 inhibitors sildenafil and vardenafil.

    Absorption is not affected by food, a further distinction from sildenafil and vardenafil, whose absorption is delayed by high-fat meals. Tadalafil is metabolized predominantly by hepatic cytochrome P450 3A4 (CYP3A4) to the pharmacologically inactive methylcatechol glucuronide conjugate; approximately 61 percent of an administered dose is excreted in feces and 36 percent in urine [5].

    The molecular mechanism is inhibition of PDE5, the enzyme responsible for hydrolysis of cGMP in vascular smooth muscle. In the corpus cavernosum, nitric oxide released during sexual stimulation activates soluble guanylate cyclase, which synthesizes cGMP from guanosine triphosphate; cGMP in turn activates protein kinase G, producing smooth muscle relaxation, vasodilation, and penile erection. By preventing cGMP degradation, tadalafil amplifies and sustains the nitric oxide signaling cascade. The same mechanism operates in the pulmonary vasculature (where PDE5 inhibition reduces pulmonary arterial pressure) and in the smooth muscle of the prostate, bladder neck, and urethra (where PDE5 inhibition alleviates lower urinary tract symptoms associated with BPH) [6, 7]. Tadalafil is more than 10,000-fold selective for PDE5 over PDE3 (cardiovascular), approximately 700-fold selective over PDE6 (retinal), but only approximately 40-fold selective over PDE11A, a dual-specificity phosphodiesterase expressed in skeletal muscle, prostate, testes, and other tissues. The relatively low PDE5/PDE11 selectivity ratio is the presumed molecular basis for the back pain and myalgia adverse events that occur at higher frequency with tadalafil than with the other PDE5 inhibitors [8, 9].

    Clinical efficacy in ED has been established across multiple randomized, double-blind, placebo-controlled trials enrolling populations with mild through severe dysfunction, with overall response rates of 60 to 70 percent on validated questionnaires. Common adverse events include headache (approximately 15 percent at 20 mg), dyspepsia (approximately 10 percent), back pain (approximately 6 percent), myalgia (approximately 4 percent), nasal congestion, and flushing. The compound is absolutely contraindicated with organic nitrates (the combination produces severe, potentially fatal hypotension) and with soluble guanylate cyclase stimulators [12, 13]. Rare but serious postmarketing signals include nonarteritic anterior ischemic optic neuropathy (NAION), sudden sensorineural hearing loss, and priapism. The compound is not recommended in patients with recent myocardial infarction, unstable angina, uncontrolled hypertension, or in patients in whom sexual activity is medically inadvisable.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • BPAP

    Tryptamine-derived synthetic monoaminergic activity enhancer (MAE) with catecholaminergic and serotonergic impulse-propagation-mediated release enhancement and TAAR1 agonism

    A benzofuran-containing synthetic enhancer substance developed by Knoll and colleagues as the most potent known monoaminergic activity enhancer, selectively amplifying impulse-dependent release of dopamine, norepinephrine, and serotonin in the brain without monoamine oxidase inhibition or amphetamine-like releasing activity.

    Abstract

    (-)1-(Benzofuran-2-yl)-2-propylaminopentane, designated (-)BPAP and also known by the developmental code FPFS-1169, is a synthetic monoaminergic activity enhancer (MAE) structurally derived from phenylpropylaminopentane (PPAP) through replacement of the phenyl ring with a benzofuran heterocycle. First described by Jozsef Knoll and colleagues in 1999, BPAP represents the most potent synthetic enhancer substance characterized to date, approximately 130-fold more potent than selegiline ((-)-deprenyl) in antagonizing tetrabenazine-induced performance inhibition in the rat shuttle box paradigm, and is the first enhancer substance to augment serotonergic neurotransmission in addition to the catecholaminergic enhancement shared with selegiline and PPAP. The compound selectively amplifies the quantity of dopamine, norepinephrine, and serotonin released per nerve impulse from monoaminergic neurons without inducing spontaneous (impulse-independent) neurotransmitter release, a pharmacological property that distinguishes it fundamentally from amphetamine-type releasing agents and from monoamine oxidase inhibitors. The mechanism of the enhancer effect has been attributed, on the basis of pharmacological antagonism studies using the selective antagonist EPPTB, to agonism at trace amine-associated receptor 1 (TAAR1), which triggers PKC-dependent phosphorylation of SNARE complex proteins and vesicular monoamine transporter 2 (VMAT2), thereby increasing vesicular monoamine accumulation and exocytotic release. At substantially higher concentrations, BPAP also inhibits monoamine reuptake (predominantly dopamine and norepinephrine), though this activity is not considered pharmacologically relevant at the low nanogram-per-milliliter concentrations that produce the enhancer effect. In preclinical pharmacology, BPAP has demonstrated neuroprotective activity against N-methyl(R)salsolinol-induced apoptosis in human dopaminergic SH-SY5Y neuroblastoma cells through stabilization of mitochondrial membrane potential and upregulation of anti-apoptotic Bcl-2 protein expression. The compound upregulates synthesis and secretion of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) in cultured mouse astrocytes, with NGF secretion increased up to 120-fold over control at optimal concentrations. Pharmacokinetic characterization in rats indicates oral bioavailability with peak plasma levels at 30 to 60 minutes, a secondary peak at approximately 4 hours consistent with enterohepatic recirculation, a terminal elimination half-life of 5.5 to 5.8 hours, blood-brain barrier penetration with distribution to multiple brain regions, and predominantly urinary excretion with greater than 90 percent recovery in excreta within 72 hours. No human clinical trials have been conducted with BPAP as of the date of this monograph. The compound remains an investigational research tool with potential therapeutic relevance to neurodegenerative disease (Parkinson’s disease, Alzheimer’s disease), depression, and age-related cognitive decline. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • KW-6356

    Selective non-xanthine adenosine A2A receptor antagonist and inverse agonist

    A second-generation, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin as a successor to istradefylline for the treatment of Parkinson’s disease, distinguished by insurmountable antagonism, inverse agonist activity, and approximately 100-fold greater receptor affinity than the first-generation A2A antagonist class.

    Abstract

    KW-6356 (sipagladenant; CAS 858979-50-7) is a selective, non-xanthine adenosine A2A receptor antagonist and inverse agonist developed by Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin) as a next-generation successor to istradefylline (NOURIANZ/NOURIAST) for the treatment of motor and non-motor symptoms of Parkinson’s disease. The compound exhibits approximately 100-fold greater binding affinity for the human adenosine A2A receptor than istradefylline (pKi 9.93 versus approximately 7.9), with a Kd of 0.13 nM and a Ki of 0.12 nM at the human A2A receptor, and demonstrates greater than 100-fold selectivity over the A1, A2B, and A3 adenosine receptor subtypes [1]. In contrast to istradefylline, which acts as a surmountable antagonist, KW-6356 exhibits two pharmacologically distinct properties: insurmountable antagonism (the capacity to suppress receptor signaling in a manner that cannot be fully overcome by increasing agonist concentration) and inverse agonism (the capacity to reduce constitutive, agonist-independent receptor activity below basal levels). X-ray crystallography of the KW-6356-bound human A2A receptor at 2.30 angstrom resolution (PDB: 8GNE) has revealed that interactions with His250 (position 6.52) and Trp246 (position 6.48) are essential for the inverse agonist activity, while deep orthosteric pocket contacts and stabilization of the extracellular loop conformation contribute to the insurmountable antagonism [1].

    The clinical development program evaluated KW-6356 in two pivotal Phase 2 studies in Japanese Parkinson’s disease populations.

    Population pharmacokinetic modeling identified food status, baseline serum albumin, and baseline body weight as covariates, but none had clinically meaningful impact on KW-6356 or M6 exposure [8]. The most common adverse events in the Phase 2a monotherapy trial were constipation (7.3 percent at 3 mg, 6.9 percent at 6 mg) and nasopharyngitis (7.3 percent at 3 mg, 8.6 percent at 6 mg) [2].

    Despite positive proof-of-concept results across both monotherapy and adjunct-to-levodopa settings, Kyowa Kirin announced discontinuation of the KW-6356 development program in July 2022, citing evaluation of the global regulatory landscape, development hurdles, and timelines for potential market entry rather than efficacy or safety concerns [9]. The discontinuation followed Lundbeck’s earlier decision to return ex-Asia development rights to Kyowa Kirin. No Phase 3 trials were initiated. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Telmisartan

    Non-peptide angiotensin II type 1 receptor antagonist with selective partial peroxisome proliferator-activated receptor gamma agonism

    A biphenyl-benzimidazole angiotensin II receptor blocker developed at Boehringer Ingelheim, distinguished from other sartans by intrinsic partial agonist activity at the nuclear peroxisome proliferator-activated receptor gamma and downstream metabolic, anti-inflammatory, and neuroprotective activity.

    Abstract

    Telmisartan is a non-peptide, orally active antagonist of the angiotensin II type 1 receptor (AT1R) and a selective partial agonist of the nuclear peroxisome proliferator-activated receptor gamma (PPARgamma), approved by the United States Food and Drug Administration in 1998 for the treatment of hypertension and subsequently for cardiovascular risk reduction in patients intolerant to angiotensin-converting enzyme inhibitors. The compound is marketed as Micardis (Boehringer Ingelheim) and is available in extensive generic competition worldwide. Among the eight clinically marketed angiotensin II receptor blockers (ARBs), telmisartan is distinguished by three pharmacological and pharmacokinetic features: the longest terminal elimination half-life (approximately 24 hours), the largest volume of distribution (approximately 500 liters), and a structurally defined partial agonist interaction with PPARgamma that is not shared at clinically meaningful potency by any other marketed sartan. These pleiotropic activities extend the pharmacological profile of telmisartan substantially beyond the hemodynamic consequences of AT1R blockade and have driven a preclinical and clinical research literature encompassing metabolic syndrome, type 2 diabetes prevention, neuroprotection, renoprotection, and anti-inflammatory applications.

    The clinical evidence base for telmisartan is anchored by two landmark randomized controlled trials. The TRANSCEND trial (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease; N = 5,926) demonstrated that telmisartan modestly reduced the composite of cardiovascular death, myocardial infarction, or stroke compared with placebo in ACE-inhibitor-intolerant patients, leading to the 2009 FDA supplemental indication for cardiovascular risk reduction [3]. Additional large-scale trials include PRoFESS (Prevention Regimen for Effectively Avoiding Second Strokes; N = 20,332), which evaluated telmisartan for secondary stroke prevention, and DETAIL (Diabetics Exposed to Telmisartan and Enalapril; N = 250), which demonstrated renoprotective non-inferiority to enalapril in type 2 diabetic patients with early nephropathy.

    The compound is poorly soluble in water but freely soluble in dimethyl sulfoxide and dimethylformamide. Telmisartan does not require dose adjustment for renal impairment but should be used with caution in severe hepatic impairment owing to the predominantly biliary elimination pathway.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cerebrolysin

    Porcine brain-derived neurotrophic peptide mixture with multimodal neuroprotective and neurorestorative activity

    A standardized enzymatic hydrolysate of porcine brain tissue yielding low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic, neuroprotective, and neuroplasticity-promoting effects across stroke, traumatic brain injury, and neurodegenerative disease models.

    Abstract

    Cerebrolysin is a standardized, injectable preparation of enzymatically derived low-molecular-weight neuropeptides and free amino acids obtained from porcine brain tissue, manufactured by EVER Neuro Pharma (formerly EBEWE Pharma) in Unterach, Austria. The preparation contains peptide fragments exclusively below 10,000 Daltons in molecular weight, including sequences homologous to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), together with approximately 15 percent free amino acids by mass. First developed in 1949 by Gerhard Harrer at the University of Graz and subsequently refined through enzymatic hydrolysis standardization at EBEWE Pharma beginning in 1972, the compound has been registered as a pharmaceutical product in over 50 countries (excluding the United States, Canada, the United Kingdom, and most Western European Union member states) for indications including stroke recovery, traumatic brain injury, and dementia syndromes.

    The pharmacological profile of Cerebrolysin is characterized by multimodal neurotrophic and neuroprotective activity. The constituent peptides activate tropomyosin receptor kinase (Trk) signaling pathways, particularly TrkA and TrkB, initiating downstream MAPK/ERK and PI3K/Akt cascades that regulate neuronal survival, differentiation, and synaptic plasticity. Additional characterized mechanisms include inhibition of calpain-mediated cytoskeletal degradation, suppression of excitotoxic glutamate signaling, reduction of free radical formation, attenuation of microglial activation, and promotion of neurogenesis in the subventricular zone and hippocampal dentate gyrus. The low molecular weight of the constituent peptides permits transit across the blood-brain barrier, a property that distinguishes Cerebrolysin from recombinant full-length neurotrophic factors that do not achieve meaningful central nervous system concentrations after peripheral administration.

    The clinical evidence base encompasses more than 200 clinical studies involving over 10,000 patients across stroke, traumatic brain injury, Alzheimer’s disease, vascular dementia, and pediatric neurodevelopmental indications. The Cerebrolysin Acute Stroke Treatment in Asia (CASTA) trial in 1,070 patients did not demonstrate superiority on the primary endpoint (National Institutes of Health Stroke Scale at day 90), although post hoc analysis in severe stroke (NIHSS greater than 12) showed a trend favoring Cerebrolysin. In Alzheimer’s disease, a meta-analysis of randomized controlled trials demonstrated significant improvement in cognitive function (standardized mean difference negative 0.40 on the ADAS-cog at 4 weeks) and global clinical change compared to placebo, with safety comparable to placebo. In traumatic brain injury, 27 clinical studies enrolling 9,752 patients have demonstrated improvements in consciousness level, cognitive performance, and neurological outcomes.

    The safety profile across controlled clinical trials is favorable, with adverse event rates comparable to placebo in most analyses. The principal adverse events are vertigo, agitation, feeling hot, headache, and dizziness. Rare anaphylactic reactions have been reported. The compound is contraindicated in epilepsy and severe renal impairment. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Bronchogen

    Synthetic bronchopulmonary tetrapeptide bioregulator with epigenetic gene-regulatory and anti-inflammatory activity targeting bronchial epithelium

    A synthetic tetrapeptide (H-Ala-Asp-Glu-Leu-OH; ADEL) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as an ultrashort peptide bioregulator with bronchopulmonary tissue-specific proliferative, anti-inflammatory, and epithelial-regenerative activity targeting bronchial epithelium, ciliated cell restoration, and respiratory mucosal barrier function.

    Abstract

    Bronchogen (H-Ala-Asp-Glu-Leu-OH; ADEL tetrapeptide; molecular formula C18H30N4O9; molecular weight 446.45 g/mol) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the bronchopulmonary-specific member of the Khavinson ultrashort peptide bioregulator family [1, 2]. The compound belongs to a class of synthetic two-to-seven-residue peptide sequences modeled on tissue-specific peptide fragments isolated from mammalian organ extracts, and is designated as the respiratory system bioregulator within this peptide family. Bronchogen is structurally related to but distinct from the other Khavinson tetrapeptides that share the Ala-Glu-Asp tripeptide core (Cardiogen, Cortagen, Epithalon); the ADEL sequence carries a different arrangement of the acidic residues (Asp at position two, Glu at position three) and a hydrophobic leucine residue at the C-terminus, a configuration that determines bronchial tissue specificity within the Khavinson classification system [3, 4]. The principal molecular mechanism of Bronchogen, characterized through molecular modeling, cell culture, organotypic bronchial tissue studies, and animal models of obstructive lung disease, is epigenetic regulation of gene expression through direct interaction of the tetrapeptide with double-stranded DNA and with histone proteins, producing chromatin remodeling and reactivation of transcriptional programs in bronchial epithelial cells [5, 6, 7]. The bronchopulmonary activity, characterized in organotypic lung tissue cultures from young and aged rats, human bronchial epithelial cell cultures across multiple passages, and nitrogen dioxide-induced chronic obstructive pulmonary disease (COPD) rat models, includes stimulation of bronchial epithelial cell proliferation and differentiation with upregulation of differentiation markers in aging cell cultures [8, 9], regulation of Ki67, Mcl-1, p53, CD79, and endothelial nitric oxide synthase (NOS-3) protein expression in human bronchial epithelium [5], restoration of normal ciliated epithelial architecture with reduction of goblet cell hyperplasia and squamous metaplasia in COPD models [10], normalization of proinflammatory cytokine profiles and neutrophilic inflammation in bronchoalveolar lavage fluid [10, 11], and enhancement of secretory immunoglobulin A and surfactant protein B production indicating recovery of respiratory mucosal barrier and surfactant function [11]. No formal pharmacokinetic studies have been published for Bronchogen as the isolated synthetic ADEL tetrapeptide. As a linear tetrapeptide with unprotected termini, the compound is expected to undergo rapid proteolytic degradation by aminopeptidases and carboxypeptidases in plasma and gastrointestinal fluid; however, molecular modeling studies have demonstrated that ultrashort peptides are substrates of the proton-coupled oligopeptide transporter (PEPT1/PEPT2) family carriers, supporting intestinal absorption and cellular uptake through active transport mechanisms [12, 13]. No human clinical trials have been published. The compound is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. Bronchogen is registered in the Russian Federation as a biologically active additive and is commercially available there in capsule formulations. It is supplied internationally as a research-grade lyophilized peptide by multiple peptide synthesis vendors at greater than 95 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • L-Carnitine

    Endogenous quaternary ammonium compound functioning as an obligate cofactor in mitochondrial long-chain fatty acid beta-oxidation via the carnitine palmitoyltransferase shuttle system

    A conditionally essential nutrient and FDA-approved pharmaceutical (levocarnitine) that mediates the translocation of long-chain fatty acyl groups across the inner mitochondrial membrane, with clinical applications spanning primary and secondary carnitine deficiency, cardiovascular secondary prevention, hemodialysis support, exercise performance, male reproductive health, and neuroprotection.

    Abstract

    L-Carnitine (levocarnitine) is a naturally occurring, water-soluble quaternary ammonium compound biosynthesized from the amino acids lysine and methionine in liver, kidney, and brain, and obtained exogenously from dietary sources (principally red meat and dairy products) and from pharmaceutical or nutraceutical supplementation. The compound is an obligate cofactor for the carnitine palmitoyltransferase (CPT) shuttle system, the sole mechanism by which long-chain fatty acyl-coenzyme A esters cross the inner mitochondrial membrane to undergo beta-oxidation. In the absence of adequate carnitine, mitochondrial long-chain fatty acid oxidation is impaired, producing the metabolic phenotype of primary systemic carnitine deficiency: hypoketotic hypoglycemia, cardiomyopathy, skeletal myopathy, and hepatic encephalopathy. The compound was first isolated from vertebrate muscle extract by Gulewitsch and Krimberg in 1905, structurally characterized as beta-hydroxy-gamma-trimethylaminobutyric acid by Tomita and Sendju in 1927, identified as the insect growth factor vitamin BT by Fraenkel and colleagues in the 1950s, and functionally linked to fatty acid oxidation by Fritz in 1955. Its obligate role in mitochondrial bioenergetics was established through the subsequent characterization of the CPT I, carnitine-acylcarnitine translocase (CACT), and CPT II enzyme system by McGarry, Foster, Ramsay, and colleagues in the 1970s and 1980s.

    L-Carnitine is approved by the United States Food and Drug Administration as levocarnitine (Carnitor, Leadiant Biosciences) for the treatment of primary systemic carnitine deficiency and for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing maintenance hemodialysis. Pharmacokinetics are characterized by carrier-mediated intestinal absorption via the organic cation/carnitine transporter OCTN2 (SLC22A5), with oral bioavailability of 54 to 87 percent from dietary sources but only 14 to 18 percent from high-dose oral supplements owing to saturation of active transport. Renal handling is dominated by efficient tubular reabsorption (90 to 99 percent of filtered load) via OCTN2 at physiological plasma concentrations, with saturable reabsorption kinetics producing rapid urinary clearance of supraphysiological doses.

    Clinical evidence for supplemental L-carnitine spans multiple therapeutic domains. In cardiovascular secondary prevention, a 2013 meta-analysis of 13 controlled trials (N = 3,629) by DiNicolantonio et al. in Mayo Clinic Proceedings reported a 27 percent reduction in all-cause mortality (OR 0.73, 95% CI 0.54 to 0.99), a 65 percent reduction in ventricular arrhythmias, and a 40 percent reduction in angina development in patients following acute myocardial infarction. In chronic heart failure, a 2017 meta-analysis of 17 trials (N = 1,625) reported significant improvements in left ventricular ejection fraction (+4.14%), stroke volume (+8.21 mL), and cardiac output (+0.88 L/min). In hemodialysis populations, Cochrane and systematic reviews have reported potential benefits for anemia, C-reactive protein reduction, and intradialytic hypotension, though evidence quality remains low to moderate. Acetyl-L-carnitine, a physiological ester derivative, has demonstrated efficacy in randomized controlled trials for diabetic peripheral neuropathy, with significant pain reduction and nerve fiber regeneration.

    A safety consideration of growing importance is the gut microbial conversion of L-carnitine to trimethylamine (TMA), which undergoes hepatic oxidation by flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a metabolite epidemiologically associated with increased atherosclerotic cardiovascular disease risk. The TMAO pathway is diet-dependent and microbiome-dependent, with omnivorous individuals producing substantially more TMAO from carnitine challenge than vegetarians or vegans. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.